List of CytomX Therapeutics patents

Patents where

Current Assignee

Name

CytomX Therapeutics

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 9644016 Soluble notch receptor proproteins and methods of use thereof	Patent 9644016 was granted and assigned to CytomX Therapeutics on May, 2017 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	9644016	May 9, 2017
‌ US Patent 10513549 Cleavage-activatable interferon-alpha proprotein	Patent 10513549 was granted and assigned to CytomX Therapeutics on December, 2019 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	10513549	December 24, 2019
‌ US Patent 10301380 Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof	Patent 10301380 was granted and assigned to CytomX Therapeutics on May, 2019 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	10301380	May 28, 2019
‌ US Patent 8993266 Proproteins activatable interferon alpha	Patent 8993266 was granted and assigned to CytomX Therapeutics on March, 2015 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	8993266	March 31, 2015
‌ US Patent 11667687 Masked activatable interferon constructs	Patent 11667687 was granted and assigned to CytomX Therapeutics on June, 2023 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	11667687	June 6, 2023
‌ US Patent 11472875 Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof		CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	11472875	October 18, 2022
‌ US Patent 11548944 Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof	Patent 11548944 was granted and assigned to CytomX Therapeutics on January, 2023 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	11548944	January 10, 2023
‌ US Patent 11548943 Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof	Patent 11548943 was granted and assigned to CytomX Therapeutics on January, 2023 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	11548943	January 10, 2023
‌ US Patent 10059762 Anti-EGFR activatable antibodies	Patent 10059762 was granted and assigned to CytomX Therapeutics on August, 2018 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	10059762	August 28, 2018
‌ US Patent 11046759 Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof	Patent 11046759 was granted and assigned to CytomX Therapeutics on June, 2021 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	11046759	June 29, 2021
‌ US Patent 10118961 Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWV	Patent 10118961 was granted and assigned to CytomX Therapeutics on November, 2018 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	10118961	November 6, 2018
‌ US Patent 9688748 Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof	Patent 9688748 was granted and assigned to CytomX Therapeutics on June, 2017 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	9688748	June 27, 2017
‌ US Patent 9127053 Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof	Patent 9127053 was granted and assigned to CytomX Therapeutics on September, 2015 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	9127053	September 8, 2015
‌ US Patent 9453078 Modified antibody compositions, methods of making and using thereof	Patent 9453078 was granted and assigned to CytomX Therapeutics on September, 2016 by the United States Patent and Trademark Office.		CytomX Therapeutics	United States Patent and Trademark Office	9453078	September 27, 2016
‌ US Patent 11365233 Activatable cytokine constructs and related compositions and methods		CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	11365233	June 21, 2022
‌ US Patent 10138272 Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof	Patent 10138272 was granted and assigned to CytomX Therapeutics on November, 2018 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	10138272	November 27, 2018
‌ US Patent 11028126 Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof	Patent 11028126 was granted and assigned to CytomX Therapeutics on June, 2021 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	11028126	June 8, 2021
‌ US Patent 11867695 Compositions and methods for detecting protease activity in biological systems	Patent 11867695 was granted and assigned to CytomX Therapeutics on January, 2024 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	11867695	January 9, 2024
‌ US Patent 9562073 Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof	Patent 9562073 was granted and assigned to CytomX Therapeutics on February, 2017 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	9562073	February 7, 2017
‌ US Patent 10179817 Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof	Patent 10179817 was granted and assigned to CytomX Therapeutics on January, 2019 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	10179817	January 15, 2019
‌ US Patent 10336824 Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof	Patent 10336824 was granted and assigned to CytomX Therapeutics on July, 2019 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	10336824	July 2, 2019
‌ US Patent 9545442 Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof	Patent 9545442 was granted and assigned to CytomX Therapeutics on January, 2017 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	9545442	January 17, 2017
‌ US Patent 9889211 Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof	Patent 9889211 was granted and assigned to CytomX Therapeutics on February, 2018 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	9889211	February 13, 2018
‌ US Patent 11992528 Compositions and methods for conjugating activatable antibodies	Patent 11992528 was granted and assigned to CytomX Therapeutics on May, 2024 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	11992528	May 28, 2024
‌ US Patent 10513558 Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof	Patent 10513558 was granted and assigned to CytomX Therapeutics on December, 2019 by the United States Patent and Trademark Office.	CytomX Therapeutics	CytomX Therapeutics	United States Patent and Trademark Office	10513558	December 24, 2019

Results per page:

60 results

0 selected

60 results

0 selected